IJCS | Volume 32, Nº2, March/April 2019

116 1. U.S.Food & Drug (FDA). FDA. Medication Guide Coumadin [Internet]. [Cited in 2016 Mar 29] Available from: http://www.fda.gov/ downloads/Drugs/DrugSafety/ucm088578.pdf 2. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: Antithrombotic therapy and prevention of thrombosis. 9th ed. AmericanCollege of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141 (Suppl 2):7s-47s. 3. Bonate PL, Ahamadi M, Budha N, de la Penã A, Earp JC, Hong Y, et al. Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. J Pharmacokinet Pharmacodyn. 2016; 43(2):123-35. 4. Lu Y, Shen D, Pietsch M, Nagar C, Fadli Z, Huang H, et al. A novel algorithm for analyzing drug-drug interactions from MEDLINE literature. Sci Rep.2015 Nov 27;5:17357. 5. Weitz JI. Blood coagulation and anticoagulant. Fibrinolytic. and antiplatelet drugs. In: Goodman & Gilman. The pharmacological basis of therapeutic. 12nd.ed. NewYork: McGrawHill/Artmed; 2010. chap.30 6. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C. et al. Guidelines on oral anticoagulation with warfarin. Br J Haematol. 2011;154(3):311-24. 7. Castro TA. Heineck I. Interventions to improve anticoagulation with warfarin. Ther Drug Monit. 2012;34(2):209-16. 8. Kotirum S, Chaiyakunapruk N, Jampachaisri K, Wattanasombat S, Rojnuckarin P. Utilization review of concomitant use of potentially interacting drugs in Thai Patients using warfarin therapy. Pharmacoepidemiol Drug Saf. 2007;16(2):21622. 9. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2016 [Internet]. [Cited in 2016 Mar 19].Available from: http://www.whocc.no/atc_ddd_index/ 10. MICROMEDEX® HEALTHCARE SERIES [Internet]. Versão 5.1. Grenwood Village. Colo: Thomson Micromedex; 2016. 11. Ferreira SMA. A importância das interações medicamento-alimento no controle da terapêutica com varfarina. (Dissert). Lisboa: Universidade Lusófona de Humanidades e Tecnologias. Faculdade de Ciências e Tecnologias da Saúde; 2012. 12. Schimidt L, Speckman J, Ansel J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in- therapeutic range. J Thromb Thrombol. 2003;15(3):213-6. 13. Gavronski M, Hartikainen S, Zharkovsky A. Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more. Pharm Pract (Granada). 2012; 10(1):9-16. 14. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk. and how best to identify such patients. Thromb Haemost. 2009;102(2):268-78. 15. Pelegrino F, Dantas RAS, Corbi ISA, Carvalho ARS. Perfil sócio demográfico e clínico de pacientes em uso de anticoagulantes orais. Rev Gaúcha Enferm. 2010;31(1):123-8. 16. Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Sci. 2006;9(3):427-33. 17. Teklay G, Shiferaw N, Legesse B, Bekele ML. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thromb J. 2014 Sep 17;12:20. 18. Penning-van Best FJ, Koerselman J, Herings RMC. Quantity and quality of potential drug interaction with coumadin anticoagulants. Pharm World Sci. 2007;29(6):271-5. 19. Benhamoua Y, Le Cam-Duchezb V, Schneller JM, Cailleux N, Magnec JC, Soubrane JC, et al. Lévesque a Expérience d’un centre de suivi et de conseil des traitements anticoagulants oraux en médecine de ville: résultats à cinq ans. Anticoagulation clinics for outpatients: A 5-year experience. Rev Med Interne. 2009;30(7):567-72. 20. Pottegard A, Christensen RP, Wang SV, Gagne JJ, Larsen TB, Hallas J. Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists. Pharmacoepidemiology Drug Saf. 2014;23(11):1160-7. 21. Wood MD, Delate T, Clark M, Clark N, Horn JR, Witt DM. An evaluation of the potential drug interaction between warfarin and levothyroxine. J Thromb Haemost. 2014;12(8):1313-9. 22. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concomitant use of warfarin with potentially interacting drugs. Pharmacotherapy. 2004:24(12):1668-74. 23. Ribeiro RA, Duncan BB, Ziegelmann PK, Stella SF, Vieira JL, Restelatto LMF, et al. Cost-effectiveness of high. Moderate and low-dose statins in the prevention of vascular events in the brazilian public health system Arq Bras Cardiol. 2015;104(1):15-9. 24. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-34. 25. Prados CMA, Castro LA, Santiago ER. PPIs: between overuse and under prescription when really necessary . Rev Esp Enferm. 2015;107(11):99-102. 26. Westegaard ML, Hansen EH, Glumer C, Jensen RH. Prescription pain medications and chronic headache in Denmark: implications for preventingmedication overuse. Eur J Clin Pharmacol.2015;71(7):851-60. 27. Holbrook A, Schulman S, Witt D, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl):e152S-e184S. References Colet et al. Adverse events in warfarin users Int J Cardiovasc Sci. 2019;32(2)110-117 Original Article Study Association This article is part of the thesis of Doctoral submitted byChristiane de Fátima Colet, fromUniversidade Federal do Rio Grande do Sul. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Federal University of Rio Grande do Sul under the protocol number 36.259/2013. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.